Revision hip replacement is the fastest-growing type line in the global hip replacement devices market, advancing at 8.47% a year and lifting its share of revenue from 13% in 2025 to 15.7% in 2034. The ground it gains comes out of primary hip replacement, whose share slips from 68.5% to 64% over the same years.
Contrive Datum Insights has published "Hip Replacement Devices Market Size, Share & Industry Analysis, By Type, Application, Material, Fixation technique, Age group, and Regional Forecast, 2026-2034". The study sizes the market at USD 8.1 billion in 2025 and USD 8.5 billion in 2026, and projects USD 13.8 billion by 2034, a compound annual growth rate of 6.24% across the forecast period. Revision hip replacement itself grows from USD 1.053 billion to USD 2.1666 billion in that window.
Why Revision Procedures Outrun the Market
Hip replacement devices are implant systems (femoral stems, acetabular cups, femoral heads and liners) that surgeons use to replace a damaged or worn hip joint. Revision procedures replace a device implanted earlier that has failed or worn out, and they are the type line most exposed to the market's main driver: rising global prevalence of hip osteoarthritis and an aging population. The study rates the impact of that driver as high and names it the largest single contributor to growth.
Other lines also beat the market average. Ambulatory surgical centers grow at 8.98%, and ceramic-on-ceramic bearings grow at 8.77%, both well ahead of the 6.24% headline rate. Hospitals still lead the application axis with 78% of 2025 revenue, at USD 6.318 billion.
The study frames the outlook with three scenarios. The base case reaches USD 13.8 billion in 2034. A bull case, built on quicker adoption of outpatient surgical center procedures and premium ceramic and robotic-assisted systems, reaches USD 14.9 billion. A bear case, built on reimbursement tightening and tender-driven pricing pressure, reaches USD 12.7 billion.
Regional Picture and the Counterweight
North America is the largest region, with 45% of 2025 revenue at USD 3.645 billion, rising to USD 5.7132 billion by 2034. The United States alone accounts for USD 3.171 billion in 2025, or 39.1% of global revenue. Asia Pacific gains the most ground: its share climbs from 22% in 2025 to 27.4% in 2034, and its revenue grows from USD 1.782 billion to USD 3.7812 billion. Middle East and Africa stays the smallest region at 4% in both years.
The report segments the market across five axes (type, application, material, fixation technique and age group), with revenue and a growth rate for every line in every year from 2020 to 2034. It covers all five regions with country-level breakdowns, the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.
Against the momentum in revision work, the largest segment moves more slowly. Primary hip replacement holds 68.5% of 2025 revenue, worth USD 5.5485 billion, and remains the largest line through 2034. It grows at only 5.44%, below the market's 6.24%, so the biggest block of revenue is also the one pulling the average down. Cementless fixation leads its axis with 58% of 2025 revenue, and patients aged 65 and above account for 71%, which keeps volume anchored in the core primary procedure even as the faster lines pull ahead.